R723 activity in cell-based assays
| Assay . | Target . | IC50, nM . |
|---|---|---|
| Ba/F3-EPOR-JAK2V617F proliferation | JAK2 V617F | 191 |
| UKE1 proliferation | JAK2 V617F | 168 |
| SET2 proliferation | JAK2 V617F | 139 |
| EPO-dependent human CD34+ progenitor proliferation | JAK2 | 124 |
| Ba/F3-EPOR-JAK2V617F pSTAT5 FACS | JAK2 V617F | 390 |
| SET2 pSTAT5 FACS | JAK2 V617F | 39 |
| IL-2 CTLL2 proliferation | JAK1/JAK3 | 528 |
| IL-2 human primary T-cell proliferation | JAK1/JAK3 | 1260 |
| IL-2 CTLL2 pSTAT5 FACS | JAK1/JAK3 | 2300 |
| IL-2 human primary T-cell pSTAT5 FACS | JAK1/JAK3 | 2700 |
| Ba/F3-JAK1V658F proliferation | JAK1 V658F | 885 |
| CMK proliferation | JAK3 A572V | 2340 |
| A549 proliferation | Multiple | 3680 |
| H1299 proliferation | Multiple | 4100 |
| IgE CHMC tryptase | Syk | 760 |
| Insulin HeLa pAKT in cell western | InsR | 10 800 |
| VEGF HUVEC pVEGFR in cell western | VEGFR | 3250 |
| Assay . | Target . | IC50, nM . |
|---|---|---|
| Ba/F3-EPOR-JAK2V617F proliferation | JAK2 V617F | 191 |
| UKE1 proliferation | JAK2 V617F | 168 |
| SET2 proliferation | JAK2 V617F | 139 |
| EPO-dependent human CD34+ progenitor proliferation | JAK2 | 124 |
| Ba/F3-EPOR-JAK2V617F pSTAT5 FACS | JAK2 V617F | 390 |
| SET2 pSTAT5 FACS | JAK2 V617F | 39 |
| IL-2 CTLL2 proliferation | JAK1/JAK3 | 528 |
| IL-2 human primary T-cell proliferation | JAK1/JAK3 | 1260 |
| IL-2 CTLL2 pSTAT5 FACS | JAK1/JAK3 | 2300 |
| IL-2 human primary T-cell pSTAT5 FACS | JAK1/JAK3 | 2700 |
| Ba/F3-JAK1V658F proliferation | JAK1 V658F | 885 |
| CMK proliferation | JAK3 A572V | 2340 |
| A549 proliferation | Multiple | 3680 |
| H1299 proliferation | Multiple | 4100 |
| IgE CHMC tryptase | Syk | 760 |
| Insulin HeLa pAKT in cell western | InsR | 10 800 |
| VEGF HUVEC pVEGFR in cell western | VEGFR | 3250 |